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Transcription of the human PRL (hPRL) gene in the
pituitary is subject to tissue-specific and multihor-
monal regulation involving two main regulatory re-
gions, a proximal promoter and a distal enhancer.
In this report we show that thyroid hormone in-
hibits the expression of the hPRL gene in rat pitu-
itary cells. Transient expression experiments show
that thyroid hormone regulation involves a strong
inhibitory element, located in the proximal (2164/
235) promoter, which is modulated by a more dis-
tal stimulatory response control region. Gel retar-
dation experiments reveal that the thyroid
hormone receptor does not bind to the proximal
negative element.
We show the existence of an activating protein-1
(AP-1) response element located at positions 261
to 254 of the proximal promoter, conferring AP-1
stimulation to the hPRL promoter. This AP-1 induc-
tion is abolished when hormone-bound thyroid
hormone receptor is present, indicating that there
is an interference between the thyroid hormone
receptor and AP-1 regulatory pathways.
Furthermore, using the complete hPRL upstream
region, we show that estrogen induction is abol-
ished by simultaneous thyroid hormone treatment.
(Molecular Endocrinology 11: 986–996, 1997)
INTRODUCTION
In vertebrates, thyroid hormone (T3) regulates a vast
array of biological processes, including metamorpho-
sis, development, growth, metabolism, and ho-
meostasis, mainly through specific regulation of gene
transcription (1). The effects of T3 are mediated by
thyroid hormone receptors (TRs) belonging to the large
nuclear hormone receptor superfamily (2, 3). Some
members of this superfamily, such as the estrogen and
glucocorticoid receptors, bind to conserved hormone
response elements (AGGTCA and AGAACA, respec-
tively) in the promoter regions of target genes. The
binding of TR to thyroid hormone response elements
(TREs) is apparently more complex. TREs vary con-
siderably in nucleotide sequence and with regard to
the number, spacing, and arrangement of binding sites
(4–7). Most TREs described to date are composed of
two or more copies of the motif (A/G)GG(A/T)CA (or a
related sequence) arranged as palindromes or direct
repeats. The spacing of these half-sites is critical for
TR homodimer formation or heterodimerization with
other members of the nuclear receptor superfamily,
such as the retinoic acid (RAR and RXR) and vitamin D
receptors (8). Most well known TREs mediate positive
regulation by thyroid hormone. Negative T3 response
elements (nTREs) have been less well characterized,
being sometimes described as half-site sequences to
which TR would bind as a monomer (9). Functional
interactions between various nuclear receptors and
between such receptors and other transcription fac-
tors are well documented (10–14).
Recently, thyroid hormone receptors have been
shown to inhibit gene expression by interfering with
the activity of the activating protein-1 (AP-1) transcrip-
tion factor (15–22). This factor is a dimer whose com-
ponents are respectively encoded by the jun/fos pro-
tooncogene family (23). It binds to a specific DNA
sequence (ATGAGTCA) and stimulates gene tran-
scription in response to activation of the protein kinase
C pathway (24). TRs exert their inhibitory effect
through direct interaction with the AP-1 complex in
solution, leading to the formation of a transcriptionally
inactive TR/AP-1 complex. TRs do not compete with
AP-1 for DNA binding sites (15).
PRL is a hormone essentially secreted by the ante-
rior pituitary. Transcription of the human PRL (hPRL)
gene in the pituitary is subject to tissue-specific and
multihormonal regulation involving the POU domain
transcription factor Pit-1 (25–28). In the 59-flanking
sequence of the hPRL gene, two regulatory regions
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have been identified, a proximal promoter (2250/235)
containing three Pit-1-binding sites and a distal en-
hancer (22000/21200) with eight additional Pit-1-
binding sites (29, 30). Regulation of hPRL gene tran-
scription by phorbol esters, epidermal growth factor,
TRH, Ca21, and cAMP depends on elements located
within the first 250 bp of the promoter (31–34). Estro-
gens are reported to stimulate hPRL gene expression
through a response element next to the distal en-
hancer (34). Nothing is known about T3 regulation of
hPRL, whereas contradictory results have been ob-
tained in GH pituitary tumor cell lines for rat PRL (rPRL)
T3 regulation. T3 was found to inhibit rPRL promoter-
driven transcription (35–37) in GH1 cells but to stimu-
late it in GH4C1 cells (38) through the same response
element, located in the proximal promoter (coordi-
nates 2176/211). From studies in GH3 cells, two TREs
were identified in the rPRL gene: a positive response
element in the distal enhancer next to the estrogen
receptor response element and a negative response
element in the 292-bp span of the proximal promoter
(39).
This report focuses for the first time on the regula-
tion of the hPRL gene by thyroid hormone. We show
that the hPRL gene promoter contains both a positive
and a negative TRE. The negative effect is stronger
than the positive one and involves cross-talk between
TR and AP-1.
RESULTS
The hPRL Promoter Is Inhibited by Thyroid
Hormone
To identify possible T3 response elements in the 59-
flanking region of the hPRL gene, we used various
constructs containing either the complete 5000-bp
pituitary hPRL promoter or a 59-deleted portion of it
fused to the chloramphenicol acetyltransferase (CAT)
reporter gene (29). The constructs were introduced by
electroporation into GH3B6 cells (a PRL-producing
pituitary cell line). Figure 1 shows the CAT activity
produced by each construct in the absence and pres-
ence of T3 as well as the inhibition factor in the pres-
ence of T3.
A construct containing the 500-bp promoter region
of the human placental lactogen B gene (hCS-B, con-
struct p500CSBCAT) (14) was used as a positive con-
trol. In this construct, T3 causes 4-fold stimulation of
reporter gene expression (0.25-fold repression). As
expected, constitutive thymidine kinase (TK)-driven
CAT gene expression is unaffected by T3 treatment. In
contrast, expression from all hPRL constructs is inhib-
ited in the presence of T3. The shorter constructs
(p250PRLCAT and p740PRLCAT) are inhibited ap-
proximately 4-fold, whereas the longer ones (p1330-
PRLCAT, p1750PRLCAT, p2627PRLCAT, p3500-
PRLCAT, and p5000PRLCAT) are inhibited only 2-fold.
Similar results were obtained in GC cells (data not
shown). These results suggest the presence of two
distinct T3 response elements in the hPRL promoter
whatever pituitary cell line used. One response ele-
ment, located in the 250-bp proximal promoter, would
mediate a strong inhibitory effect; the second, located
between coordinates 21330 and 2740, would have a
weaker positive effect, attenuating the inhibitory effect
of the proximal region.
The Inhibitory Effect Is not Pit-1 Dependent
The first 250 bp of the hPRL promoter (proximal pro-
moter) include three well known Pit-1-binding sites
(30). They also include the A site involved in the re-
sponses to cAMP, TRH, and Ca21 (32, 33) (Fig. 2a). To
study T3 regulation in this proximal region, we tested
two constructs: one bearing the entire proximal region
without the TATA box (bp 2250/235) and one bearing
the same fragment lacking the P3 Pit-1-binding site
(bp 2164/235). Both proximal promoter segments
were cloned in front of the TK promoter fused with the
CAT reporter gene. The constructs were introduced by
electroporation into GH3B6 cells (Fig. 2b). As a positive
control we used a construct containing three palin-
dromic TRE sequences cloned in front of the TK-CAT
fusion. As expected, T3 stimulates CAT expression
Fig. 1. Influence of T3 on hPRL Promoter Activity
GH3B6 cells were transfected by electroporation with 30
mg of the indicated fusion construct. The various PRLCAT
constructs carry 59-deletions of the hPRL promoter (decreas-
ing in length from p5000PRLCAT to p250PRLCAT). Construct
p500CSBCAT carries the human placental lactogen promoter
fused to the CAT reporter gene. Plasmid pTKCAT (or
pBLCAT2) carries the CAT reporter gene under the control of
the TK promoter. Electroporated cells were incubated for
48 h in medium with or without 10 nM T3. Cells were har-
vested, and CAT activity was assayed in cell lysates. The
percentage of CAT conversion in the absence (hatched
boxes) or presence (gray boxes) of T3 is shown, and the ratio
between these values is indicated to the left as fold repres-
sion for each construct. Values are the mean 6 SEM of five
independent transfections, each performed in duplicate.
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Fig. 2. T3 Regulation of a Heterologous Promoter in Pituitary and Nonpituitary Cells
A, Sequence of the sense strand of the 217-bp hPRL promoter (57). The positions of the three proximal, high affinity
Pit-1-binding sites and of the A sequence are indicated, respectively, by boxes P1, P2, P3, and A. B, GH3B6 cells were transfected
with 15 mg of the indicated plasmid. Plasmid pTKCAT carries the TK promoter fused to the CAT reporter gene. Plasmids
p(2164/235)TKCAT and p(2250/235)TKCAT additionally carry the indicated base pairs of the hPRL proximal promoter in front
of the TK promoter; p(TREpal)3XTKCAT carries instead three copies of the TREpal sequence in front of the TK promoter. Cells
were grown for 48 h in the absence or presence of 10 nM T3. CAT activity was measured, and the data are presented as described
MOL ENDO · 1997 Vol 11 No. 7
988
from this control plasmid approximately 3-fold while
having no effect on the negative control (pTKCAT),
indicating that T3 effects are specific under our exper-
imental conditions. CAT expression from both
p(2250/235)TKCAT and p(2164/235)TKCAT is inhib-
ited about 3-fold by T3. This shows that the T3 re-
sponse element can mediate inhibition of the heterol-
ogous TK promoter. Our experiments further show
that the nTRE is located between bp 2164 and 235 of
the hPRL proximal promoter.
To detect a possible involvement of Pit-1 in T3 inhi-
bition of the hPRL proximal promoter, we performed
cotransfection experiments in which nonpituitary HeLa
cells received one of the above-mentioned constructs
in combination with a vector expressing either hTRa1
complementary DNA (cDNA; pSV2c-erbAa), hPit-1
cDNA (pRSVPit-1), or both vectors (Fig. 2c). Expres-
sion from pTKCAT is unaffected by the presence of
one or both of these expression vectors. As expected,
T3 stimulates expression from p(TREpal)3XTCAT in the
presence of pSV2c-erbAa; this effect is unaltered by
the additional presence of pRSVPit-1. In cells receiv-
ing either p(2250/235)TKCAT or p(2164/235)TKCAT
constructs, the presence of pSV2c-erbAa is sufficient
to promote T3 inhibition of reporter gene expression,
so clearly Pit-1 synthesis is not required for this effect.
Furthermore, the inhibition factor is the same regard-
less of whether the Pit-1 expression vector is present.
That Pit-1 is indeed synthesized in HeLa cells trans-
fected with pRSVPit-1 is shown by the increased basal
level of CAT expression recorded with p(2250/
235)TKCAT (4-fold stimulation) and p(2164/235)TK-
CAT (3-fold stimulation). These results suggest that
Pit-1 is not involved in the inhibitory effect exerted by
T3 through the proximal promoter region. We obtained
similar results in other Pit-1-deficient cell lines, such as
CV1 and JEG-3 (data not shown), reinforcing the con-
clusion that the effect of T3 on the hPRL proximal
promoter is not pituitary specific.
Involvement of Receptor-DNA Binding in the T3
Effects
The 2164/235 region contains two Pit-1-binding sites
(P1 and P2) and the cAMP response element A (Fig.
2a). A search for potential TR-binding sites in this
region revealed only one imperfect half-site, GGGTaA
(2113/2108). To test the affinity of TR for this putative
binding site, we performed gel retardation assays with
bacterially expressed TR (Fig. 3). The probes used
were an oligonucleotide containing the 2115/287
PRL proximal promoter sequence and, as a positive
control, an oligonucleotide containing the DR4 con-
sensus TR-binding sequence (two TR consensus half-
sites directly repeated, spaced by 4 bp). As expected,
we observed a retarded band with the DR4 oligonu-
cleotide, corresponding to the TR monomer (Fig. 3,
lane 2); this band disappeared in the presence of a
100-fold excess of cold DR4 oligonucleotide (lane 3),
but not in the presence of a 100-fold excess of Sp1
oligonucleotide (lane 5). Moreover, the retarded band
was supershifted in the presence of anti-TR antibodies
(lane 4). All of these results prove the specificity of the
Fig. 3. TR Does not Bind to the Proximal TRE of the hPRL
Promoter
Extracts of TR-expressing bacteria (4.5 mg protein) were
incubated with the indicated 32P-labeled DNA fragment, i.e.
either the DR4 oligonucleotide (positive control) or the (2115/
287) sequence of the proximal hPRL promoter. The presence
of competitor oligonucleotides (in 100-fold excess), anti-TR
antibody (a-TR), recombinant RXR (4.5 mg), and 10 nM T3 is
indicated by a 1.
in Fig. 1B. Black bars, Inhibition factors; hatched bars, induction factors. Values are the mean 6 SEM of four independent
transfections, each performed in duplicate. C, HeLa cells were cotransfected by calcium phosphate precipitation with 5 mg of the
indicated reporter construct and with 10 mg of each expression vector indicated. The pSV2c-erbAa expresses human TRa1;
pRSVPit-1 expresses human Pit-1; pRSVbgal, expressing b-galactosidase, was used as a control and to maintain a constant
amount of expression vector (20 mg). Cells were incubated for 48 h in the absence or presence of 10 nM T3, and CAT activity was
measured. Inhibition factors (gray bars) and induction factors (hatched bars) were calculated as described in Fig. 1B. The data
are the mean 6 SEM of five independent experiments, each performed in duplicate.
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retarded band. Addition of bacterially expressed RXR
led to the formation of TR/RXR heterodimers (lane 6),
as expected.
In contrast, TR does not specifically bind to the
proximal PRL promoter sequence (2115/287), even in
the presence of RXR or T3 (lanes 7–13). The results
were the same when the probe used was the entire
2164/235 PRL proximal sequence (data not shown).
This strongly suggests that the T3 effect in this region
occurs via an indirect mechanism that does not re-
quire TR binding to the DNA.
T3 Inhibition of the hPRL Proximal Promoter Is
Independent of the Forskolin Pathway, but
Involves an AP-1-Binding Site
To identify the indirect T3 repression mechanism, two
alternative pathways were investigated. TR has been
shown to interfere with stimulation of the PIT1 gene
promoter by forskolin (40). As the proximal hPRL pro-
moter contains cAMP response elements (2164/235)
(32, 33), we examined whether T3 treatment might
affect the response to forskolin mediated by this re-
gion. GH3B6 cells were transfected with a construct
containing the first 164 bp of the proximal promoter
cloned in front of the luciferase (LUC) reporter gene
(p164PRL-LUC). The cells were treated with forskolin
and/or T3. Gene expression increased significantly
(15-fold) in response to forskolin. T3 treatment re-
duced the basal promoter activity approximately
2-fold. When both treatments were applied, forskolin
stimulation was reduced by a factor of 2, clearly indi-
cating that forskolin and thyroid hormone act through
distinct pathways (data not shown).
In search of an alternative pathway that might be
modulated by T3, sequence analysis of the hPRL prox-
imal promoter was performed. This analysis revealed
the presence of a highly conserved AP-1 consensus
motif (261 TGAaTCAT 254) containing only one mis-
match (see also Caccavelli, L., I. Manfroid, J. A. Mar-
tial, and M. Muller, in preparation). This led us to in-
vestigate whether this putative AP-1 site is functionally
active and how destruction of this site affects the
response of the hPRL proximal promoter to T3. To this
end, we produced a mutation in the AP-1 consensus
motif of p164PRL-LUC, yielding plasmid p164(AP-
1)mPRL-LUC. We then transfected GH3B6 cells with
either p164(AP-1)mPRL-LUC, its wild-type parent, or
the control plasmid pTKLUC bearing the LUC gene
under the control of the TK promoter. The cells were
treated or not with T3. The results are shown in Fig. 4a.
T3 treatment did not affect expression from pTK-LUC,
but it inhibited expression from p164PRL-LUC (3-fold
inhibition). The mutant construct p164(AP-1)mPRL-
LUC displayed 2-fold lower basal expression and did
not respond to T3.
These results show for the first time that an AP-1
consensus sequence located close to the proximal
Pit-1-binding site P1 contributes to the basal activity
of the hPRL promoter in pituitary cells. In addition, this
Fig. 4. T3 Inhibits the Response of the hPRL Proximal Pro-
moter to the AP-1 Transcription Factor
a, GH3B6 cells were electroporated with 10 mg
p164PRL-LUC or p164(AP-1)mPRL-LUC (containing a mu-
tated AP-1 response element). As a control we used pTK-
LUC, a plasmid carrying the luciferase gene under the
control of the TK promoter. The cells were incubated for
48 h with or without 10 nM T3, and luciferase activity was
measured. Inhibition factors were calculated by dividing
the activity recorded for treated cells by that obtained with
the corresponding untreated cells. The basal LUC activity
obtained with p164(AP-1)mPRL-LUC plasmid is 2 times
less than that obtained with p164PRL-LUC. The data are
the mean 6 SEM of three independent transfections, each
performed in duplicate. b, HeLa cells were cotransfected
by calcium phosphate precipitation with 10 mg p164PRL-
LUC or p164(AP-1)mPRL-LUC and either 20 mg of the
control expression vector pRSVbgal or 5 mg of each other
expression vector indicated plus enough pRSVbgal to
reach a total of 20 mg. The cells were incubated for 48 h
with or without 10 nM T3, and luciferase activity was mea-
sured. The data are the mean 6 SEM of three independent
experiments, each performed in triplicate.
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sequence is directly involved in T3 repression of the
hPRL promoter.
T3 Abolishes AP-1 Activation of the hPRL
Promoter in Heterologous Cells
Since T3 inhibition appears to involve a putative
AP-1-binding site, we next analyzed the action of
AP-1 on the hPRL proximal promoter in nonpituitary
cells. We cotransfected HeLa cells with p164PRL-
LUC in combination with vectors expressing c-jun
and c-fos (pRSVc-jun and pRSVc-fos) and/or with
pSV2c-erbAa. It should be mentioned that none of
these vectors has any effect on reporter gene ex-
pression from control plasmid pTK-LUC (not
shown). The cells were incubated with or without T3.
Cells harboring a vector expressing b-galactosidase
cDNA (pRSVbgal) were included as a control. The
results are presented in Fig. 4b. In the presence of
T3, as expected, a 3-fold inhibitory effect is ob-
served using p164PRL-LUC only when the thyroid
hormone receptor is coexpressed. In the absence of
TR, transcription was stimulated approximately 20-
fold in the presence of c-jun and c-fos regardless of
whether T3 was present. In contrast, stimulation by
c-jun and c-fos was nearly abolished when both T3
and its receptor were present. Furthermore, muta-
tion of the consensus AP-1 site in p164(AP-1)mPRL-
LUC completely abolished both c-jun/c-fos activa-
tion and T3 inhibition of the hPRL promoter in HeLa
cells.
These results strongly suggest that AP-1 is able to
activate the hPRL promoter and that T3 exerts its
inhibitory effect via an interaction between the hor-
mone-bound receptor and the AP-1 complex.
AP-1 Binds to the hPRL Proximal Promoter
To confirm the involvement of AP-1 in hPRL expres-
sion, we performed gel retardation assays. The 264/
235 fragment was used as a probe in the presence of
AP-1-enriched HeLa cell extracts. The results are pre-
sented in Fig. 5. One retarded complex was obtained
(lane 2), which disappeared in the presence of a 100-
fold excess of an oligonucleotide containing the AP-1
consensus sequence (lane 3), but not in the presence
of the nonspecific DR4 oligonucleotide in a 100-fold
excess (lane 4). In addition, the complex disappeared
in the presence of antibodies recognizing the DNA-
binding region of c-jun (lane 5). All of these data show
that the observed band is a specific AP-1 DNA
complex.
Taken together, our results confirm the following
model for T3 inhibition of hPRL gene transcription: the
hormone-bound thyroid hormone receptor interacts
with the AP-1 complex, thereby preventing the com-
plex from activating hPRL gene transcription via the
proximal promoter.
T3 Abolishes Estradiol (E2) Stimulation of the
hPRL Promoter
The transfection experiments using 59-deletion mu-
tants of the hPRL promoter suggested the presence of
a modulatory element in the distal region (21330/
2740) that leads to a decrease in the overall T3 inhi-
bition. Preliminary studies identified a complex ele-
ment centered at 21200 that is able to bind TR and, in
addition, contains an estrogen response element (34).
To further analyze the role of this distal regulatory
region, we examined the effects of thyroid hormone
and estrogen on a fragment of the hPRL promoter
containing both the proximal promoter and the distal
regulatory region (p2627PRLCAT; Fig. 6). The results
Fig. 5. AP-1 Specifically Binds to the Proximal hPRL Pro-
moter
Total extracts from HeLa cells enriched in AP-1 factor
(described in Materials and Methods; 5 mg) were incubated
with the 32P-labeled (264/235) hPRL promoter sequence
and used in a gel retardation assay. Competition with a
100-fold excess of cold oligonucleotide and addition of anti-
Jun antibody (a-jun) are indicated by 1.
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show, as expected, that T3 exerts an approximately
3-fold inhibitory effect, and E2 has a 2-fold stimulatory
effect. In cells treated with both hormones, the re-
corded CAT activity is surprisingly low, reaching only
half the basal level. In conclusion, the impact of the
distal element on T3 regulation appears to be weak,
even when it is stimulated by estrogens.
DISCUSSION
We have studied, for the first time, the regulatory ef-
fects of thyroid hormone on the hPRL gene promoter.
We present evidence that thyroid hormone down-reg-
ulates transcription of the hPRL gene in pituitary cells.
In the hPRL promoter we have identified two main
T3-responsive regions. The first, located in the proxi-
mal promoter, mediates a strong negative effect,
whereas the second, located in the distal promoter,
mediates a weak positive response. The overall effect
of the two combined regions is repressive.
Our finding that T3 inhibits the hPRL promoter is in
keeping with the physiological data on the endoge-
nous human gene. Hypothyroidism in human patients
is frequently associated with increased serum PRL
levels, whereas hyperthyroid patients present lower
PRL levels than euthyroid control subjects (40). Al-
though it is unclear whether this effect is due to direct
regulation of the hPRL gene, recent studies on a hu-
man pituitary cell line suggest 2-fold inhibition of en-
dogenous hPRL gene transcription by T3 (41).
The Proximal Promoter
The proximal hPRL promoter mediates T3 inhibition of
a heterologous promoter (TK) in both pituitary (GH3B6)
and nonpituitary cells (HeLa, CV1, and JEG-3; Fig. 2).
On the other hand, we observe no binding of TR to the
proximal T3 response element in gel retardation as-
says (Fig. 3). This suggests that T3 acts indirectly.
Recently, T3 treatment was shown to inhibit Pit-1 gene
transcription through interference between the thyroid
hormone receptor and Pit-1 (42). As T3 inhibition of the
hPRL promoter is observed in nonpituitary cells (Fig.
2c), we can exclude an indirect action of T3 through
inhibition of Pit-1 expression. Furthermore, coexpres-
sion of Pit-1 and TR does not affect T3 inhibition in
HeLa cells (Fig. 2c), so we can rule out a mechanism
involving interference between the TR and Pit-1 lead-
ing to inhibition of the hPRL gene promoter, nor is the
forskolin pathway involved in the response of the
hPRL promoter to T3 (our data not shown). This con-
trasts with T3 inhibition of Pit-1 gene expression,
which involves interference of T3 with the cAMP in-
duction pathway (42).
An AP-1-responsive element has been located in
the hPRL proximal promoter between coordinates
261 and 254 (see also Caccavelli, L., I. Manfroid, J. A.
Martial, and M. Muller, in preparation). It contains an
AP-1-binding sequence that differs by only one mis-
match from the consensus AP-1-binding site. We
show that this sequence can specifically bind AP-1 in
gel retardation assays (Fig. 5) and that it mediates
15-fold stimulation of reporter gene transcription in the
presence of coexpressed c-jun and c-fos (Fig. 4b).
This stimulation is almost completely abolished in the
presence of hormone-bound TR. We conclude that
thyroid hormone exerts its inhibitory effect via interac-
tion of hormone-bound TR with AP-1. Furthermore,
mutation of the AP-1 site completely abolishes the
stimulatory effect of c-jun and c-fos and the inhibitory
effect of T3 (Fig. 4). This confirms that the two re-
sponses are interrelated.
The transcription-stimulating activity of AP-1 is in-
creased by protein kinase C phosphorylation.
Gellersen et al. (34) observed synergistic stimulation of
the hPRL proximal promoter (250 bp) by TPA (12-O-
tetradecanoyl-phorbol-13-acetate) treatment and
Pit-1 expression in the SKUT-1B-20 human uterine
cell line. Here we show strong stimulation of the hPRL
promoter in HeLa cells cotransfected with a reporter
construct and with c-jun and c-fos expression vectors,
but this effect is completely Pit-1 independent. This
discrepancy suggests that TPA stimulation in SKUT
1B-20 cells might involve another mechanism(s) in
addition to the increased AP-1 activity.
Several groups have reported interaction of AP-1
with members of the nuclear receptor family, e.g. the
glucocorticoid, retinoic acid, progestin, estrogen, and
Fig. 6. The Inhibitory Effect of T3 Overrides the Stimulatory
Effect of E2 Exerted via the 2627-bp hPRL Promoter Frag-
ment
GH3B6 cells were electroporated with 30 mg
p2627PRLCAT. After electroporation, the cells were incu-
bated for 48 h in the presence of the antiestrogen ICI 64384
(1 mM) and/or T3 (10 nM) or in the presence of E2 (100 nM)
and/or T3 (10 nM). CAT activity was measured, and the in-
duction factors were calculated as the ratio between the
measured activity to the value obtained with ICI-treated con-
trol cells. The data are the mean 6 SEM of five independent
experiments, each performed in duplicate.
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thyroid hormone receptors (15–22). Different mecha-
nisms have been observed for this cross-modulatory
action according to the promoter context (22). Direct
interaction between TR and AP-1 has been demon-
strated in coimmunoprecipitation assays (20). Further-
more, in gel retardation experiments, binding of AP-1
to DNA was inhibited by TR when the latter was added
before addition of the labeled binding sequence (19,
20). The hPRL proximal promoter contains one AP-1-
responsive element and no TR-binding site. This sug-
gests that TR blocks the action of AP-1 by hindering its
binding to its response element. Whether the interac-
tion between TR and AP-1 is direct or mediated by
another factor(s) is unclear.
In striking contrast to the overall inhibition of hPRL
transcription by T3, the combined positive and nega-
tive acting elements of the rPRL promoter mediate
overall activation of this promoter by T3 in GH3 cells
(39). The rPRL promoter responds differently to T3
according to the pituitary cell line examined (36–39).
Nevertheless, studies in rats have shown that treat-
ment with the antiarhythmic drug amiodarone, a T3
antagonist, reduces PRL mRNA levels (43), suggesting
that rPRL expression is up-regulated by T3. The rat
sequence corresponding to the hPRL proximal AP-1
sequence differs by three nucleotides from the AP-1
consensus binding sequence, suggesting that rat and
human PRL genes might be differently regulated by
AP-1. Indeed, recently it was shown that expression of
c-jun inhibits rat PRL expression in GH4 pituitary cells
(44). This repression involves the FPII region centered
at 2125 in the rat promoter and is only seen in GH4
cells. The proposed mechanism is an indirect binding
of c-jun to the promoter by recruitment of a pituitary-
specific FPII-binding factor. Whether T3 would be able
to block this repression, which would result in an over-
all activation by T3, is at present unknown. These
observations contrast with our results using the hPRL
promoter in GH3B6 cells. However, the same re-
searchers describe a synergistic activation of the rPRL
promoter by c-jun and Pit-1 expression in HeLa cells.
In this case, the proposed mechanism is an interaction
of c-jun with Pit-1 bound to the proximal binding site,
but again without direct DNA binding of c-jun. Nothing
is known about T3 modulation of this effect, which is
suppressed in GH4 cells by the c-jun repression de-
scribed above. Thus, it seems very likely that the
mechanism of T3 inhibition of the hPRL promoter de-
scribed here does not apply to the homologous rPRL
promoter.
Complete hPRL Promoter
The combined action of the proximal, negative pro-
moter and the distal, weakly positive region results in
inhibition by T3 of the complete upstream region. In
addition, this region contains a consensus estrogen-
responsive element (ERE) located close to a TR-bind-
ing sequence (see also Van de Weerdt, C., F. M. Per-
nasetti, L. Caccavelli, J. A. Martial, and M. Muller, in
preparation). The same hPRL ERE can mediate 2-fold
stimulation of a heterologous promoter in SKUT-
1B-20 cells, a PRL-producing uterine carcinoma cell
line (34). The fact that T3 is also able to block E2
activation of this construct (Fig. 6) stresses the impor-
tance of the T3 regulation mediated by the proximal
AP-1 site.
Activation of rPRL gene transcription by E2 involves
the stabilization of a chromatin loop permitting critical
interactions between proteins of the distal enhancer
and proximal promoter (45). Dexamethasone-bound
GR has been found to bind to the distal ERE, compet-
ing in this with estrogen receptor and preventing for-
mation of the loop (46). We have no information as to
whether a particular chromatin structure characterizes
the plasmid constructs used here, but hindering of
loop formation by TR is certainly a possible mecha-
nism of repression, especially as factors bound to the
proximal promoter are known to be important in loop
formation. If the AP-1 complex plays a role in the
interactions between the distal and proximal regions,
then T3 blocking of AP-1 binding to the DNA would
inhibit loop formation, thus preventing E2 stimulation.
Alternatively, T3 might down-regulate the expression
of other proteins necessary for the response to estro-
gen mediated by the complete hPRL promoter.
In conclusion, we demonstrate that hPRL gene tran-
scription is inhibited by thyroid hormone. We show
that the inhibitory effect of T3 involves interference
with the AP-1 transactivation mediated by an AP-1-
binding site located in the proximal hPRL promoter. A
weak positive TRE, located in the distal region close to
an ERE, modulates this inhibition. However, T3 treat-
ment reduces the E2 stimulatory effect at a promoter
region containing both proximal and distal response
elements. Thus, our work illustrates the complexity of
mechanisms involved in gene transcriptional regula-
tion. Cross-talk between nuclear receptors and other
transcription factors provides an intricate set of dis-
tinct regulatory mechanisms permitting precise con-




PRLCAT constructs with 59-deletions in the hPRL promoter
(24777, 23474, 22627, 21750, 21330, 2740, and 2250
indicate the first remaining upstream nucleotide) have been
described (30, 32). The chimeric hPRLTKCAT construct
p(2250/235)TKCAT was constructed as follows. The DNA
fragment was amplified by PCR using strategically designed
59- and 39-primers (see oligonucleotides), digested by HindIII
and XbaI, gel purified, and inserted in front of the TK promoter
by ligation into the HindIII-XbaI-digested pBLCAT2 (47)
plasmid. Plasmid p164PRL-LUC was built by digesting
p164PRLCAT (32) with BglII and HindIII, after which the hPRL
promoter fragment was gel purified and cloned into the pXP2
vector (48). Plasmid p164(AP-1)mPRL-LUC was built using
the Chameleon double stranded, site-directed mutagenesis
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kit from Stratagene (La Jolla, CA), using the mutated AP-1 m
oligonucleotide as a template. The sequence of all constructs
was verified by dideoxy chain termination sequencing. The
(TREpal)3XTKCAT construct has been described previously
(14). The expression vector pSV2c-erbAa (containing human
TRa cDNA expressed under the control of the simian virus 40
early promoter) was provided by J. Ghysdael. The pRSVc-jun
and pRSVc-fos vectors, which contain coding sequences for
c-jun and c-fos under the control of the Rous sarcoma virus
(RSV) promoter, respectively, are gifts from P. Herrlich. The
pRSVbgal and the pRSVPit-1 expression vectors have been
described previously (49, 50). All plasmids were prepared
using the Nucleobond kit from Macherey-Nagel Co. (Du¨ren,
Germany).
Oligonucleotides
The double or single stranded oligodeoxyribonucleotides
used for plasmid construction or gel mobility assays were
obtained from Eurogentec (Seraing, Belgium). The AP-1 oli-
gonucleotide contains the AP-1 site of the human collage-
nase promoter (56). The numbers represent positions in the
PRL upstream sequence, where relevant.




GCT-39; AP-1 m, 59-CTTCATGAATATAATCGAGCAGGCAT-
TCGTTTCCC-39; and Sp1, 59-AGTTCCGCCCATTCTCC-
GCCCCA-39.
Cell Cultures and Transient Transfection
GH3B6 and HeLa cells were grown in monolayers in DMEM
supplemented with 10% FCS plus E2 (5 3 10
210 M). Twenty-
four hours before transfection, the cells were grown in phenol
red-free DMEM supplemented with 2% AG1X8 resin-char-
coal-stripped FCS (52). T3, E2, and forskolin were obtained
from Sigma (Deisenhofen, Germany).
Electroporation GH3B6 cells were harvested with trypsin-
EDTA and resuspended in phenol red-free DMEM with 2%
depleted FCS (FCSt; final concentration, 2 3 106 cells/ml).
Thirty micrograms of each plasmid were mixed with 1.6 3 106
cells. The cells were then exposed to a single pulse of 250 V/4
mm and 1500 mF capacitance with an Easyject electroporator
(EquiBio, Seraing, Belgium). Transfected cells were immedi-
ately transferred to phenol red-free DMEM with 2% FCSt and
incubated for 48 h. Treatment of the electroporated cells is
detailed in the figure legends.
Calcium Phosphate Precipitation HeLa cells were trans-
fected by the CaPO4 method, as previously described (53).
The day before transfection, 5 3 105 cells were plated in petri
dishes (9 cm in diameter) in phenol red-free DMEM with 2%
FCSt. Two to 10 mg reporter plasmid were mixed with 5 mg of
each expression vector specified; the total amount of expres-
sion vector was adjusted to 20 mg by the addition of the
appropriate amount of pRSVbgal. After a 12-h incubation
with CaPO4 precipitate, the cells were washed with PBS and
incubated in phenol red-free DMEM with 2% FCSt for 48 h.
Hormone treatments are detailed in the figure legends.
CAT Assay After a 48-h incubation, the cells were har-
vested by scraping and resuspended in 100 ml 250 mM Tris-
HCl (pH 7.6). Cell disruption and the CAT assay were per-
formed as described previously (32).
Luciferase Assay After a 48-h incubation, the cells were
harvested by scraping and directly resuspended in lysis
buffer. The assays were performed as described previously
(54).
Protein concentrations in extracts were determined by the
Bradford assay. Fifty micrograms of total extract were used in
both the CAT and LUC assays.
Mobility Shift Assays
Oligonucleotides and PCR fragments were [32P]ATP labeled
using T4 polynucleotide kinase. Labeled probes were purified
by elution from polyacrylamide gels. Proteins were preincu-
bated in a buffer containing 20 mM HEPES (pH 7.8), 4 mM
MgCl2, 2 mM dithiothreitol (DTT), 10% glycerol, 0.2 mg/ml
BSA, and 80 mM KCl with 1 mg poly(dI-dC) for 30 min at 4 C.
When necessary, antibodies were preincubated with proteins
for 30 min. After preincubation, 10,000 cpm probe were
added, and incubation proceeded for 30 min at 4 C. The
resulting protein-DNA complexes were resolved by electro-
phoresis on a prerun 5% polyacrylamide gel with 0.5 3 TBE
as the running buffer for 2 h at 4 C. The gel was dried and
autoradiographed overnight. Polyclonal rabbit anti-Jun anti-
bodies were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). The antigen sequence used to produce the anti-
bodies corresponds to residues 247–263 within the C-termi-
nal DNA-binding domain of the mouse c-Jun protein. Poly-
clonal rabbit antithyroid hormone receptor a1 antibody was
purchased from Affinity Bioreagents (Neshanic Station, NJ).
The antigen sequence used to produce the antibodies cor-
responds to residues 403–410 of the extreme C-terminal
region of the human TRa, which is identical to the rat se-
quence. Recombinant RXR was provided by Dr. Baes, Uni-
versity of Leuven (Leuven, Belgium).
Bacterial Expression and Purification of hTRa1 The
bacterial strain BL21(DE3)pLYS S (55) was transformed with
the vector pET-hTRa1 (provided by L. J. De Groot). A freshly
transformed clone was used to inoculate 500 ml Luria Bertoni
medium. The culture was grown at 37 C to an OD of 0.4,
isopropyl-b-D-thiogalactoside (IPTG) was added to a 0.5-mM
final concentration, and the culture was gently rocked for 5 h
at 20 C. The bacteria were harvested by centrifugation and
resuspended in 20 ml lysis buffer (20 mM Tris, pH 8.0; 100 mM
NaCl; 0.5 mM MgCl2; 1 mM phenylmethylsulfonylfluoride; and
1% aprotinin). The suspension was sonicated on ice to obtain
a clear lysate; 2 ml of a mixture of 0.1 M DTT, 0.5 M EDTA, and
5% Nonidet P-40 were added; and bacterial debris were
removed by centrifugation at 60,000 3 g. Soluble proteins
were precipitated from the supernatant by the addition of
0.33 g/ml ammonium sulfate and recovered by centrifugation
at 60,000 3 g. The pellet was resuspended in 1 ml HS buffer
(25 mM HEPES-KOH, pH 7.6; 5 mM MgCl2; 1 mM EGTA; 1 mM
DTT; and 10% glycerol), and the solution was dialyzed
against HS buffer. The fraction was loaded on a heparin-
Sepharose column, and proteins were eluted with a linear KCl
gradient. Human TRa1 was detected in the fractions by
means of a gel retardation assay using a DR-4 probe and by
SDS-PAGE followed by Coomassie staining or Western blot-
ting. Eluates at 0.4–0.7 M KCl contained greater than 95%
pure, soluble, bacterially expressed hTRa1. We used 4 mg
purified TR extract in each gel retardation assay unless oth-
erwise indicated in the figure legends.
HeLa Cell Extracts Enriched with AP-1 Complex HeLa
cells were transfected with 25 mg pRSVc-jun and pRSVc-fos
according to the diethylaminoethyl-dextran transfection pro-
tocol (56). The cells were harvested 48 h after transfection.
Total protein extracts were prepared by resuspending the
cells in 20 mM HEPES, pH 7.8; 400 mM KCl; 20% glycerol;
and 2 mM DTT. They were disrupted by three freeze-thaw
cycles, followed by centrifugation at 12,000 rpm for 30 min.
Total enriched extract was added in each gel retardation
assay in an amount corresponding to 4.5 mg protein, as
determined by the Bradford assay.
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